Targeted Abdominal CT in Conjunction With Lung Cancer Screening

NCT ID: NCT07171190

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

6272 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-11

Study Completion Date

2027-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Early detection through screening can improve cancer survival by identifying it when it's most treatable. The NHS now offers Lung Cancer Screening (LCS) assessments to people aged 55-74 who have ever smoked. Those at higher risk of lung cancer are offered a lung scan.

This group also has a high risk of developing abdominal cancers, such as kidney cancer. A recent study explored whether it would be feasible to extend the lung scan to include the abdomen. Results showed most participants supported this addition, and the number of serious findings was similar to those detected in UK breast or bowel cancer screening programmes.

However, the abdominal scan was only offered on the day of the lung scan, giving little time for people to consider their decision. The process also added too much time to be practical for widespread implementation.

This new study will:

* Test whether mentioning the possible abdominal scan in the initial LCS invitation affects participation in LCS assessments.
* Test new processes to assess if the abdominal scan can be added to the lung scan with minimal extra time.
* Check if participants can be split between the lung scan only group and lung and abdominal scan group using an approach called 'cluster randomisation'. This will be important in case a bigger trial is needed.
* See whether the additional processes are acceptable

People aged 55-70 who are invited to the lung cancer screening will be eligible to take part in this study. Only those who are found to be at a high risk of lung cancer after their assessment, and therefore offered a lung scan, will be offered the abdominal scan, provided they have not had an abdominal scan in the previous 12 months or one booked in the next 3 months.

This study will take place in two existing lung cancer screening locations in Yorkshire.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Cell Carcinoma (Kidney Cancer) Kidney Cancers AAA - Abdominal Aortic Aneurysm Renal Stones

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Screening NHS Lung Cancer Screening Kidney cancer Abdominal cancer Lung cancer Abdominal Aortic Aneurysms (AAA) Abdominal screening

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Invitation control arm

Invited to NHS Lung Cancer Screening to assess lung cancer risk via letter or text message, following the normal process

Group Type ACTIVE_COMPARATOR

Lung Cancer Screening Invitation Intervention

Intervention Type OTHER

Participants are invited to the NHS Lung Cancer Screening to assess lung cancer risk via letter or text message

Invitation intervention arm

Will have additional text included in the standard Lung Cancer Screening letter or text explaining that, if eligible, they may also be offered a scan of their abdomen at the same time as their lungs.

Group Type EXPERIMENTAL

Lung Cancer Screening Invitation Intervention

Intervention Type OTHER

Participants are invited to the NHS Lung Cancer Screening to assess lung cancer risk via letter or text message

Scan control arm

For the scan control batches, those who are 'high risk' following the LCS assessment will have an appointment booked for LCS in the normal way by the LCS assessor.

Group Type ACTIVE_COMPARATOR

Abdominal scan intervention

Intervention Type DIAGNOSTIC_TEST

Receiving an abdominal CT scan at the same time as the lung scan.

Scan intervention arm

Those who are 'high risk' following the LCS assessment will be invited to have an abdominal CT scan at the same time as their lung scan.

Group Type EXPERIMENTAL

Abdominal scan intervention

Intervention Type DIAGNOSTIC_TEST

Receiving an abdominal CT scan at the same time as the lung scan.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lung Cancer Screening Invitation Intervention

Participants are invited to the NHS Lung Cancer Screening to assess lung cancer risk via letter or text message

Intervention Type OTHER

Abdominal scan intervention

Receiving an abdominal CT scan at the same time as the lung scan.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be eligible to be invited to the first round of a West Yorkshire and Harrogate LCS or a Humber and North Yorkshire Cancer Alliance LCS (i.e. have been identified as a smoker or ex-smoker and registered as living within the relevant LCS catchment area).
* Be registered with a GP in England.
* Be aged 55-70 years 364 days old at the date of invitation.

* Have been individually randomised to the invitation intervention arm
* Have booked in for a LCS assessment

* Have been randomised to the scan intervention cluster
* Be invited to attend for a LDCT Thorax based upon scores on either PLCOM2012 or Liverpool Lung Project (LLP) risk prediction models (PLCOM2012 risk of ≥1.51% over six years or LLPver2 five-year risk of ≥2.5%)14 during the LCS assessment.
* Have attended the lung scan appointment
* Have given electronic or written informed consent to participate

Exclusion Criteria

• None
2. Eligibility criteria for the cluster level randomisation to scan intervention or scan control


* Participant does not have capacity to give consent (standard criteria for assessing capacity apply).
* Weight or physical size exceeds restrictions for scanner (\>200kg).
* Participant unable to lie flat.
* Poor physical fitness such that treatment with curative intent would be contra-indicated.

• Had an abdominal CT in the previous 12 months or has one booked within the next 3 months.
* For HNY, this is checked before the LCS assessment. Therefore, participants will be excluded before the LCS assessment.
* For WYH, this is only checked after the LCS assessment. Therefore, anyone having had an abdominal CT in the previous 12 months or with one booked within the next 3 months will be excluded at this point (see 8.6).
3. Eligibility criteria for the process evaluation Health care professionals: Healthcare professionals involved in the delivery of LCS in any of the study areas who agree to take part.

Participants: People individually randomised to the invitation intervention arm who attend the LCS assessment or the scanning unit within the study period and who agree to be interviewed.
Minimum Eligible Age

55 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hull University Teaching Hospitals NHS Trust

OTHER_GOV

Sponsor Role collaborator

University of Cambridge

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Grant Stewart

Professor Grant Stewart

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hull Teaching Hospitals Trust

Hull, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Grant Stewart

Role: CONTACT

Phone: 01223 331199

Email: [email protected]

Jessica Kitt

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Oliver Byass

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

G128732

Identifier Type: -

Identifier Source: org_study_id